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CLINICAL OBSERVATIONS IN HEPATOLOGY
Effects of Restoring Portal Flow With Anticoagulation
and Partial Splenorenal Shunt Embolization
Nicolas M. Intagliata,1 Wael E. Saad,1,2 and Stephen H. Caldwell1
S
pontaneous portosystemic shunt (PSS) from por-
tal hypertension is associated with portal vein
(PV) stasis and chronic hepatic encephalopathy
(HE).1 Embolization of PSS is effective in select cases of
refractory HE, but is relatively contraindicated in
patients with portal vein thrombosis (PVT) (Table 1).2-8
This procedure redirects significant blood flow back
through the PV and has been reported to improve liver
function.5,9 We present a case of a new PVT in a cirrho-
sis patient with refractory HE thought secondary to PSS.
This was treated sequentially with 6 months anticoagula-
tion to achieve PV patency, followed by partial coil
embolization of a large PSS. One year later, imaging
revealed a 54% increase in liver volume.
Case Report
A 46-year-old man with cirrhosis secondary to pri-
mary sclerosing cholangitis followed for 8 years had
been noted to decline over 1 year prior to presenting
with acute onset abdominal pain and worsening HE.
Computed tomography (CT) revealed an atrophic liver
with a new PVT in a diminutive PV and increased size
of previously identified splenorenal shunt (SRS).
Endoscopy revealed no esophageal varices and small,
low-risk gastric fundal varices. The Model for Endstage
Liver Disease (MELD) score prior to warfarin therapy
was 12 (Table 2). Anticoagulation was started with
warfarin to a goal international normalized ratio (INR)
of 2-3. He continued to require hospitalization for HE
despite adherence to medical therapy. Follow-up imag-
ing 4 months after starting warfarin revealed interval
partial recanalization of the main diminutive PV with
a residual large SRS and atrophic liver. The patient
continued to struggle with severe HE and therapeutic
shunt obliteration was pursued.
A hepatic venogram and catheterization of SRS was per-
formed to evaluate hemodynamic response to shunt occlu-
sion in anticipation of future embolization. This study
revealed a patent main diminutive PV with sluggish veloc-
ities (peak velocity in the main PV 6.9 cm/s). The large
SRS demonstrated an average flow volume of 325 mL/
min. Test balloon occlusion of the SRS resulted in an
increase in main PV peak velocity to 90.1 cm/s. Next, a
partial coil embolization of the SRS was performed result-
ing in30% decreased flow (Fig. 1). Concurrent PVultra-
sound demonstrated conversion of hepatofugal blood prior
to the procedure (25 cm/s) to hepatopetal flow (20 cm/s).
The patient did very well, with a significant reduc-
tion in fatigue and marked improvement in cognition.
Biochemical indices improved (Table 2). Ascites and
high-risk esophageal varices have not developed to
date, while the platelet level has remained unchanged.
A follow-up CT scan 9 months after this procedure
revealed a 54% increase in liver volume (Fig. (Fig. 2).
Discussion
This case represents successful sequential therapy of
a PVT with anticoagulation to reestablish patency,
Table 1. Reported Series Evaluating Therapy for
Encephalopathy With Shunt Embolization in Cirrhosis
Study Study Design Study Subjects
Uflacker et al. 19877 Case series 5
Fukuda et al. 20018 Case series 11
Zidi et al. 20073 Case series 7
Mukund et al. 20126 Case series 7
Laleman et al. 20132 Multicenter retrospective
cohort
37
Singh et al. 20134 Case series 10
An et al. 20145 Single center retrospective
case control
17
Abbreviations: CT, computed tomography; HE, hepatic encephalopathy; INR,
international normalized ratio; MELD, Model for Endstage Liver Disease;
PSS, portosystemic shunt; PV, portal vein; PVT, portal vein thrombosis; SRS,
splenorenal shunt.
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followed by partial occlusion of a large PSS. A recent
multicenter retrospective study was published from
Europe demonstrating that embolization of PSS in
patients with refractory HE is safe and effective in
select cases.2 This study found that patients with a
MELD of less than 11 responded best to therapy.
Notably, patients with PVT were excluded.
Since antiquity, as recounted in the Greek myth of
Prometheus, the remarkable capabilities of the liver to
regenerate have fascinated mankind.10 Moreover, surgi-
cal advancements in partial hepatic resection and living
donor liver transplantation have built upon this under-
standing.11 Chronic or acute ischemia from thrombo-
sis can result in hepatocyte apoptosis and atrophy,
potentially resulting in worsening liver function and
progressive liver disease.12 Recently, Villa et al.13
showed that prevention of PVT with prophylactic
enoxaparin decreased the incidence of PVT, and
reduced decompensation events. Reduction in blood
flow by micro and macro thrombosis and/or redirec-
tion of flow through a PSS (both present in this case)
may deprive the liver of important components
(growth factors and cytokines) necessary to compensate
for chronic injury. Reversal of this process with antico-
agulation and redirection of blood flow through the
liver may offer important therapeutic benefit.
Whether this case represents true hepatic regenera-
tion is unclear, as we did not conduct functional
Fig. 1. A retrograde in subtracted venogram of the distal splenore-
nal shunt (SRS) as it empties into the left renal vein (LRV) after partial
coil embolization.
Fig. 2. Liver volume measurement before and after partial shunt
embolization. (A) The CT-reconstructed liver volume measured at
873 mL prior to partial shunt embolization. (B) CT-reconstructed liver
volume measured at 1,346 mL 9 months after partial shunt
embolization.
Table 2. Clinical Course Over Time
Pre PVT PVT Pre-SRS Embolization Postembolization Until Present
Timeline
Total bilirubin (mg/dL) 1.2 1.4 1.6 0.6
Creatinine (mg/dL) 0.7 0.7 0.8 0.8
INR 1.4 1.5 3.0* 2.9*
Albumin (g/dL) 3.3 2.9 3.0 4.0
MELD 11 12 — —
CTP score B(7) B(7) — —
Liver volume (mL) — — 873 1346
Encephalopathy? Yes Yes Yes No
*Warfarin-effect of INR does not allow accurate calculation of MELD and CTP. PVT, portal vein thrombosis; SRS, splenorenal shunt; mth, month; INR, international
normalized ratio; MELD, model for endstage liver disease; CTP, Childs-Turcotte-Pugh; CT, computed tomography scan.
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testing and instead relied on CT-reconstructed volu-
metric comparison. We are limited by inherent poten-
tial inaccuracies of indirect volume measurement and
did not account for volume status of the patient.
However, we suspect (as evidenced by clinical and bio-
chemical improvement in the patient) some compo-
nent of hepatic regeneration occurred with the
restoration of portal venous flow to the liver.
Redirection of blood flow likely served to reduce
stasis and augment better perfusion by way of the
diminutive PV. In this case, we believe the combina-
tion of anticoagulation and embolization simultane-
ously reduced HE and improved hepatic function. As
this procedure can exacerbate portal hypertension,
more studies are needed to delineate which particular
patients may benefit the most.
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